Biovitrum creates the Nordic region's largest CRO in early drug discovery
An independent research company, iNovacia based in central Stockholm, has been formed following a management buyout from Biovitrum, one of the largest biopharma companies in Europe.
An independent research company, iNovacia based in central Stockholm, has been formed following a management buyout from Biovitrum, one of the largest biopharma companies in Europe.
With 35 experienced pharmaceutical developers, iNovacia has the specialist competence to develop projects from concept to lead compounds, as well as 1,000m2 of laboratory space, making it the Nordic region's largest contract research organisation (CRO) in early drug discovery.
Biovitrum will continue to be a customer for early-stage pharmaceutical projects, said Biovitrum's ceo Mats Pettersson.
iNovacia recently entered into an alliance with Asinex, a company within the pharmaceutical chemicals sector, with principal operations in Moscow. Asinex will hold approximately 20% of the shares of iNovacia, which will gain access to a chemical library for the development of new chemicals in return.